Targeting Hsp90 for the treatment of cancer

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 4, 2006, Pages 483-495

  Drysdale, Martin J ^a   Brough, Paul A ^a   Massey, Andrew ^a   Jensen, Michael Rugaard ^b   Schoepfer, Joseph ^b  

^a Vernalis PLC   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

17 AAG; HDAC; Heat shock protein; Histone deacetylase; Hsp70; Hsp90; Molecular chaperone

Indexed keywords

1 (2 PHENOL) 2 NAPHTOL DERIVATIVE; 1,5 DIPHENYL PYRAZOLE DERIVATIVE; 17 AAG; 17 DMAG; 6 AMINOPURINE 3; ANSAMYCIN DERIVATIVE; CARBOXYFLUORESCEIN; CCT 018159; G 3129; G 3130; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IPI 504; PU24FCL; PURINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; RADANAMYCIN; RADESTER; RADICICOL; RESORCINOL DERIVATIVE; RHODAMINE; TAMOXIFEN; TRIAZOLOPYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG; VER 49009;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CLINICAL TRIAL; DRUG BINDING SITE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GASTROINTESTINAL TUMOR; HUMAN; LIVER TOXICITY; METASTASIS; MOLECULAR PROBE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; OVARY CANCER; PROSTATE CANCER; PROTEIN PROCESSING; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG DELIVERY SYSTEMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS;

EID: 33746128911     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Maloney A, Workman P: Hsp90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther (2002) 2(1):3-24.
2. Isaacs JS, Xu W, Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3(3):213-217.
3. Workman P: Altered states: Selectively drugging the Hsp90 cancer chaperone. Trends Mol Med (2004) 10(2):47-51.
4. Dymock BW, Drysdale MJ, McDonald E, Workman P: Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin Ther Pat (2004) 14(6):837-847.
5. Whitesell L, Lindquist SL: Hsp90 and the chaperoning of cancer. Nat Rev Cancer (2005) 5(10):761-772. Provides an excellent review of the biology of Hsp90 and its role in cancer.
6. Janin YL: Heat shock protein 90 inhibitors. A textbook example of medicinal chemistry? J Med Chem (2005) 48(24):7503-7512.
7. Chiosis G, Rodina A, Moulick K: Emerging Hsp90 inhibitors: From discovery to clinic. Anticancer Agents Med Chem (2006) 6(1):1-8.
8. Chiosis G: Targeting chaperones in transformed systems - a focus on Hsp90 and cancer. Expert Opin Ther Targets (2006) 10(1):37-50.
9. Blagg BSJ, Kerr TD: Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev (2006) 26(3):310-338.
10. Kamal A, Boehm MF, Burrows FJ: Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med (2004) 10(6):283-290.
11. Neckers L, Neckers K: Heat shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs (2005) 10(1):137-149.
12. Workman P: Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett (2004) 206(2):149-157.
13. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH: Geldanamycin, a new antibiotic. J Antibiot (1970) 23(9):442-447.
14. Rinehart KL Jr: Antibiotics with ansa rings. Ace Chem Res (1972) 5(2):57-64.
15. Sasaki K, Rinehart KL Jr, Slomp G, Grostic MF, Olson EC: Geldanamycin. I. Structure assignment J Am Chem Soc (1970) 92(26):7591-7593.
16. Rinehart KL Jr, Shield LS: Chemistry of the ansamycin antibiotics. Fortschr Chem Org Naturst (1976) 33:231-307.
17. Andrus MB, Meredith EL, Simmons BL, Sekhar BB, Hicken EJ: Total synthesis of (+(-geldanamycin and (-)-o-quinogeldanamycin with use of asymmetric anti- and syn-glycolate aldol reactions. Org Lett (2002) 4(20):3549-3552.
18. Andrus MB, Meredith EL, Hicken EJ, Simmons BL, Glancey RR, Ma W: Total synthesis of (+(-geldanamycin and (-)-o-quinogeldanamycin: Asymmetric glycolate aldol reactions and biological evaluation. J Org Chem (2003) 68(21):8162-8169.
19. Snader KM: Benzoquinone ansamycins. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DG, Newman DJ (Eds), CRC Press, Boca Raton, FL, USA (2005):339-356.
20. Miyata Y: Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des (2005) 11(9):1131-1138.
21. Uehara Y: Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets (2003) 3(5):325-330.
22. Neckers L, Schulte TW, Mimnaugh E: Geldanamycin as a potential anticancer agent: Its molecular target and biochemical activity. Invest New Drugs (1999) 17(4):361-373.
23. Porter JR, Ge J, Normant E, Ali J, Dembski MS, Gao Y, Georges AT, Grenier L, Pak R, Patterson J, Sydor JR et al. Synthesis and biological evaluation of IPI-504, an aqueous soluble analog of 17-AAG and potent inhibitor of Hsp90. 231st American Chemical Society National Meeting, Atlanta, GA, USA (2006):MEDI-210.
24. Infinity Pharmaceutical Inc: Infinity Initiates Phase I Clinical Trial of IPI-504 for Patients with Gastrointestinal Stromal Tumors (GIST). Press Release (2006) January 10.
25. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes HER2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol (2001) 8(3):289-299. Discloses the first fully synthetic, small-molecule inhibitors of Hsp90, that is, the PU class.
26. Dymock B, Barril X, Beswick M, Collier A, Davies N, Drysdale M, Fink A, Fromont C, Hubbard RE, Massey A, Surgenor A et al: Adenine derived inhibitors of the molecular chaperone Hsp90-SAR explained through multiple X-ray structures. Bioorg Med Chem Lett (2004) 14(2):325-328. This reference, along with reference [27], provides a crystallographic description of the PU class of Hsp90 inhibitors.
27. Wight L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A et al: Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem Biol (2004) 11(6):775-785. This reference, along with reference [26], provides a crystallographic description of the PU class of Hsp90 inhibitors.
28. Howes R, Barril X, Dymock BW, Grant K, Northfield CJ, Robertson AG, Surgenor A, Wayne J, Wright L, James K, Matthews T et al: A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem (2006) 350(2):202-213.
29. Lucas B, Rosen N, Chiosis G: Facile synthesis of a library of 9-alkyl-8-benzyl-9H-purin-6-ylamine derivatives. J Comb Chem (2001) 3(6):518-520.
30. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N: Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER2 tyrosine kinase. Bioorg Med Chem (2002) 10(11):3555-3564.
31. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G: Targeting wide-range oncogenic transformation via PU24FCI, a specific inhibitor of tumor Hsp90. Chem Biol (2004) 11(6):787-797.
32. Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G: Evaluation of 8-arylsulfanyl, 8-arylsulfinyl and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem (2005) 48(8):2892-2905.
33. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G: Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem (2006) 49(1):381-390.
34. Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC et al: Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem (2006) 49(2):817-828. Describes the first orally active small-molecule inhibitiors of Hsp90 to demonstrate efficacy in a mouse xenograft model.
35. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, Aherne W: High-throughput screening assay for inhibitors of heat shock protein 90 ATPase activity. Anal Biochem (2004) 327(2):176-183.
36. McLaughlin SH, Smith HW, Jackson SE: Stimulation of the weak ATPase activity of human Hsp90 by a client protein. J Mol Biol (2002) 315(4):787-798.
37. Avila C, Kornilayev BA, Blagg BS: Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorg Med Chem (2006) 14(4):1134-1142.
38. Zhou V, Han S, Brinker A, Klock H, Caldwell J, Gu Xj: A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal Biochem (2004) 331(2):349-357.
39. Schilb A, Riou V, Schoepfer J, Ottl J, Muller K, Chene P, Mayr LM, Filipuzzi I: Development and implementation of a highly miniaturized confocal 2D-FIDA-based high-throughput screening assay to search for active site modulators of the human heat shock protein 90β. J Biomol Screen (2004) 9(7):569-577.
40. Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N, Chiosis G: Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J Biomol Screen (2004) 9(5):375-381.
41. Llauger-Bufi L, Felts SJ, Huezo H, Rosen N, Chiosis G: Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg Med Chem Lett (2003) 13(22):3975-3978.
42. Cheung KM, Matthews TP, James K, Rowlands MJ, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl L, Aheme W et al: The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett (2005) 15(14):3338-3343. Provides a discussion of early compounds in the resorcinol pyrazole class of Hsp90 inhibitors.
43. Kreusch A, Han S, Brinker A, Zhou V, Choi HS, He Y, Lesley SA, Caldwell J, Gu XJ: Crystal structures of human Hsp90α-complexed with dihydroxyphenylpyrazoles. Bioorg Med Chem Lett (2005) 15(5):1475-1478.
44. Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley S, Webb P, Workman P et al: Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem (2005)48(13):4212-4215. Describes the evolution of the resorcinol pyrazole series by structure-based design.
45. Brough PA, Barril X, Beswick M, Dymock BW, Drysdale MJ, Wright L, Grant K, Massey A, Surgenor A, Workman P: 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4- carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg Med Chem Lett (2005) 15(23):5197-5201.
46. Barril X, Beswick MC, Collier A, Drysdale MJ, Dymock BW, Fink A, Grant K, Howes R, Jordan AM, Massey A, Surgenor A et al: 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorg Med Chem Lett (2006) 16(9):2543-2548.
47. Shen G, Blagg BS: Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org Lett (2005) 7(11):2157-2160.
48. Wang M, Shen G, Blagg BS: Radanamycin, a macrocylic chimera of radicicol and geldanamycin. Bioorg Med Chem Lett (2006) 16(9):2459-2462.
49. Atrash B, Cooper TS, Sheldrake P, Workman P, McDonald E: Development of synthetic routes to macrocyclic compounds based on the Hsp90 inhibitor radicicol. Tetrahedron Lett (2006) 47(13):2237-2240.
50. Cooper TS, Atrash B, Sheldrake P, Workman P, McDonald E: Synthesis of resorcinylic macrocycles related to radicicol via ring-closing metathesis. Tetrahedron Lett (2006) 47(13):2241-2243.
51. Barill X, Brough P, Drysdale M, Hubbard RE, Massey A, Surgenor A, Wright L: Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett (2005) 15(23):5187-5191.
52. Munster PN, Srethapakdi M, Moasser MM, Rosen N: Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res (2001) 61(7):2945-2952.
53. Neckers L, Ivy SP: Heat shock protein 90. Curr Opin Oncol (2003) 15(6):419-424.
54. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 425(6956):407-410. Provides evidence to suggest that in tumour cells Hsp90 predominantly exists in a multi-protein, super-chaperone complex with a higher affinity for 17-AAG than is exhibited by Hsp90 in normal cells.
55. Gooljarsingh LT, Fernandes C, Yan K, Zhang H, Grooms M, Johanson K, Sinnamon RH, Kirkpatrick RB, Kerrigan J, Lewis T, Amone M, King AJ, Lai Z, Copeland RA, Tummino PJ: A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci USA (2006) 103(20):7625-7630. This article suggests an alternative kinetic explanation for the observed higher potency of some Hsp90 inhibitors in cell culture and possibly in vivo.
56. Chen X, Bies RR, Ramanathan RK, Zuhowski EG, Trump DL, Egorin MJ: Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. Cancer Chemother Pharmacol (2005) 55(3):237-243.
57. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL: Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol (2001) 47(4):291-302.
58. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ: Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2- dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol (2005) 55(1):21-32.
59. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L et al: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol (2005) 23(9): 1885-1893.
60. Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, Brown AP, Levine BS, Covey JM, Egorin MJ, Eiseman JL et al: Preclinical toxicity of a geldanamycin analog, 17-(dimethyl-aminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: Potential clinical relevance. Cancer Chemother Pharmacol (2005) 56(6):637-647.
61. Supko JG, Hickman RL, Grever MR, Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol (1995) 36(4):305-315.
62. Beliakoff J, Whitesell L: Hsp90: An emerging target for breast cancer therapy. Anticancer Drugs (2004) 15(7):651-662.
63. DeFranco DB, Csermely P: Steroid receptor and molecular chaperone encounters in the nucleus. (2000) Sci STKE 2000(42):PE1.
64. Pratt WB, Galigniana MD, Morishima Y, Murphy PJ: Role of molecular chaperones in steroid receptor action. Essays Biochem (2004) 40:41-58.
65. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L: Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/neu. Proc Natl Acad Sci USA (2002) 99(20):12847-12852.
66. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science (1997) 275(5308):1943-1947.
67. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem (2002) 277(42):39858-39866.
68. Osbome CK: Tamoxifen in the treatment of breast cancer. N Engl J Med (1998) 339(22):1609-1618.
69. Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, Sporn E, Jakesz R: Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin Cancer Res (2002) 8(11):3427-3432.
70. Lykkesfeldt AE, Madsen MW, Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res (1994) 54(6):1587-1595.
71. Lykkesfeldt AE, Sorensen EK: Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol (1992) 31(2):131-138.
72. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L: Destabilization of steroid receptors by heat shock protein 90-binding drugs: A ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res (2001) 7(7):2076-2084.
73. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L: Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res (2003) 9(13):4961-4971.
74. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Res (2003) 63(9):2139-2144.
75. Burger AM, Fiebig HH, Stinson SF, Sausville EA: 17-(Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs (2004) 15(4):377-387.
76. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI et al: 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 8(5):986-993.
77. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW: The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res (2005) 65(11):4929-4938.
78. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, Whitesell L: Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90-binding agents. Clin Cancer Res (2000) 6(8):3312-3318.
79. Hoang AT, Huang J, Rudra-Ganguly N, Zheng J, Powell WC, Rabindran SK, Wu C, Roy-Burman P: A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol (2000) 156(3):857-864.
80. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA: In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino- 17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol (2005) 56(2):115-125.
81. Nguyen DM, Lorang D, Chen GA, Stewart JH 4th, Tabibi E, Schrump DS: Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: In vitro and in vivo analysis. Ann Thorac Surg (2001) 72(2):371-378.
82. Yin X, Zhang H, Burrows F, Zhang L, Shores CG: Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res (2005) 11(10):3889-3896.
83. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P: DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 91(22):1940-1949.
84. Yang J, Yang JM, Iannone M, Shin WJ, Lin Y, Hait WN: Disruption of the EF-2 kinase/Hsp90 protein complex: A possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res (2001) 61(10):4010-4016.
85. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S et al: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol (2005) 23(6):1078-1087.
86. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM et al: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 11(9):3385-3391.
87. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P: Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res (2005) 11(19 Pt 1):7023-7032.
88. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Wallon M et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 23(18):4152-4161. Provides evidence for clear tumour pharmacodynamic responses in patients receiving 17-AAG, and also tumor stasis in two malignant melanoma patients.
89. Gabai VL, Budagova KR. Sherman MY: Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene (2005) 24(20):3328-3338.
90. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res (2005) 65(22):10536-10544. Describes evidence that abrogation of Hsp70 induction by siRNA increases the apoptotic potential of Hsp90 inhibitors in leukemia cell models.
91. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J et al: Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood (2005) 105(3):1246-1255.
92. Zaarur N, Gabai VL, Porco JA Jr, Calderwood S, Sherman MY: Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res (2006) 66(3): 1783-1791.
93. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 18(5):601-607. Provides evidence that HDAC6 is the HDAC responsible for Hsp90 deacetylation, and that this deacetylation is crucial for the maturation of the glucocorticoid receptor.
94. Aoyagi S, Archer TK: Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol (2005) 15(11):565-567.
95. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB: Regulation of the dynamics of Hsp90 action on the glucocorticoid receptor by acetylation/ deacetylation of the chaperone. J Biol Chem (2005) 280(40):33792-33799.
96. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E et al: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 280(29):26729-26734.
97. Chen L, Meng S, Wang H, Ball P, Bai W, Li B, Atadja P, Bhalla KN, Wu J: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther (2005) 4(9):1311-1319.
98. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K: Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of HER-2. Clin Cancer Res (2005) 11(17):6382-6389.
99. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S: Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp (2004) 259:249-266.
100. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS: Modulation of p53, ErbB1, ErbB2 and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 94(7):504-513.
101. Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S: Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol (2005) 67(4):1166-1176.
102. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K: Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood (2005) 105(4):1768-1776.